Report an error

Spotted something inaccurate in “SGLT2 Inhibitors Cut Kidney Progression 37%, but Evidence Quality Is Weak”? Tell us what’s wrong and we’ll check it against the original source.

Cancel

This form is for factual corrections. We read every report but cannot reply individually.